Dual-mode probe for detecting hydrogen sulfide and use thereof
US-2024390529-A1 · Nov 28, 2024 · US
US2016287731A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016287731-A1 |
| Application number | US-201415035936-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 13, 2014 |
| Priority date | Nov 14, 2013 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
Opening claim text (preview).
1 - 19 . (canceled) 20 . A conjugate of the formula B-L-P or a pharmaceutically acceptable salt thereof, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands, PSMA binding ligands, and PSMA inhibitors, L is a divalent linker, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a precursor thereof, or a radical of a compound capable of binding a radionuclide or radionuclide containing group, such as a metal chelating group. 21 . The conjugate of claim 20 comprising folate-Asp, 22 . The conjugate of claim 20 comprising folate-Arg. 23 . The conjugate of claim 20 wherein the linker comprises a polypeptide comprising lysine, arginine, or aspartic acid, or a combination thereof. 24 . The conjugate of claim 20 wherein the linker does not include a diradical of the formula NH—(CH 2 ) 2 —NH, 25 . The conjugate of claim 20 comprising the formula or a derivative thereof comprising a chelated metal. 26 . The conjugate of claim 20 comprising folate-PEG. 27 . The conjugate of claim 26 comprising the formula or a derivative thereof comprising a chelated metal. 28 . The conjugate of claim 26 comprising the formula or a derivative thereof comprising a chelated metal. 29 . The conjugate of claim 20 wherein the targeting agent is a radical of a PSMA binding ligand or PSMA inhibitor. 30 . The conjugate of claim 29 comprising the formula where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or where W is O or S. 31 . The conjugate of claim 29 wherein the linker comprises a polypeptide comprising phenylalanine, lysine, arginine, or aspartic acid, or a combination thereof. 32 . The conjugate of claim 29 comprising the formula or a derivative thereof comprising a chelated metal. 33 . The conjugate of claim 29 comprising the formula where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 34 . The conjugate of claim 29 wherein the linker comprises the formula 35 . The conjugate of claim 29 wherein the linker comprises the formula 36 . The conjugate of claim 33 comprising the formula or a derivative thereof comprising a chelated metal. 37 . The conjugate of claim 20 , wherein the radionuclide is a positron-emitting radionuclide. 38 . The conjugate of claim 37 , wherein the positron-emitting radionuclide is selected from the group consisting of 89 Zr, 45 Ti, 51 Mn, 64 Cu, 61 Cu, 63 Zn, 82 Rb, 68 Ga, 66 Ga, 11 C, 13 N, 15 O, 124 I, 34 Cl, 18 F, and 19 F. 39 . The conjugate of claim 20 wherein the radionuclide is a radiotherapy agent.
Antineoplastic agents · CPC title
of the prostate · CPC title
Detection or diagnosis of diseases · CPC title
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title
conjugates with a carrier being an organic compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.